Chinese vaccine safe and immune response in early stages of trial


A candidate vaccine against covid-19 that is being developed in China has shown to be safe and able to induce an immune response in healthy volunteers in the early stages of the clinical trial, according to the results released this Friday.

The conclusions of the initial phase clinical trial, which were published this Friday in the scientific journal The Lancet Infectious Diseases, also point to positive levels of tolerance to all doses tested, with no reports of serious adverse reactions among participants.

The first tests of BBIBP-CorV, a potential inactivated vaccine against covid-19 that is being developed in China, involved more than 600 healthy volunteers, between 18 and 80 years old, allowing to evaluate the effects also in a group of older people .

According to the results, antibody responses were detected in all volunteers 42 days after vaccination, encouraging news for researchers.

“Protecting older people is a central goal of a successful vaccine, as this age group is at a higher risk of serious illness. However, vaccines are sometimes less effective in these groups, because the immune system weakens with age“explained one of the authors, Xiaoming Yang.

Among participants over 60, the response was still slower, taking 42 days for antibodies to be detected in all participants in that age group, compared with the 28 days required for younger participants.


Please enter your comment!
Please enter your name here